

Table A1. Brand Approval and Generic Entry for Psychotherapeutic Medications, 2000-2008

Drug Class	Brand		Generic	
	Name	Approval Date	Name	Entry Date
Antidepressants				
<i>SSRIs</i>	Luvox	1994	Fluvoxamine	2000
	Prozac	1987	Fluoxetine	2001
	Paxil	1992	Paroxetine	2003
	Celexa	1998	Citalopram	2004
	Zoloft	1991	Sertraline	2006
	Lexapro	2002	Escitalopram	2006
<i>SNRIs</i>	Effexor	1993	Venlafaxine	2006
	Pristiq	2008	Desvenlafaxine	Brand Only
<i>Norepinephrine-dopamine reuptake inhibitors</i>	Wellbutrin/ Zyban	1985 (Wellbutrin), 1997 (Zyban)	Bupropion	1996
<i>Second Generation</i>	Serzone	1994	Nefazodone	2003
<i>MAO Inhibitors</i>	Parnate	1961	Tranylcypromine	2006
	Marplan	Prior to 1982	Isocarboxazid	Brand Only
<i>Tricyclics/ Tetracyclics</i>	Remeron	1996	Mirtazapine	2003
	Surmontil	1979	Trimipramine	2006
	Tofranil	1984	Imipramine	2008
	Vivactil	1995	Protriptyline	2008
	Anafranil	1989	Clomipramine	1996
	Norpramin	Prior to 1982	Desipramine	1987
	Pamelor	Prior to 1982	Nortriptyline	1992
	Emsam	2006	Selegiline transdermal patch	Brand Only
Antipsychotics				
<i>Atypical</i>	Clozaril	1989	Clozapine	1996 Brand Only
	Abilify	2002	Aripiprazole	Brand Only
	Zyprexa	1996	Olanzapine	Brand Only
	Risperdal	1993	Risperidone	2008 Brand Only
	Geodon	2001	Ziprasidone	Brand Only

Table A2. New Indications for Antipsychotic Medications

Brand Name	Generic Name	New Indication
Abilify	Aripiprazole	Pediatric BPD; adolescent Schizophrenia; adjunctive therapy; adult bipolar disorder
Seroquel	Quetiapine	Maintenance for bipolar disorder
Risperdal Consta	Risperidone	Bipolar I disorder
Seroquel	Quetiapine	Maintenance for bipolar disorder
Seroquel-XR	Quetiapine	Bipolar disorder, depression; mania; adjunctive treatment

Table 3A. Psychotropic medication growth rate using complete MarketScan Commercial Claims database and only those contributors who continuously contributed to the MarketScan database over the study time period

